A phase 1-2, multicenter, open-label study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 given in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

Trial Profile

A phase 1-2, multicenter, open-label study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 given in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2012

At a glance

  • Drugs AEG 35156 (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aegera Therapeutics
  • Most Recent Events

    • 31 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned end date changed from 1 Jan 2009 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 08 Jan 2009 First patient has been dosed. Recruitment for this trial is expected to be completed prior to the end of 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top